[go: up one dir, main page]

MX2019003035A - Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra. - Google Patents

Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.

Info

Publication number
MX2019003035A
MX2019003035A MX2019003035A MX2019003035A MX2019003035A MX 2019003035 A MX2019003035 A MX 2019003035A MX 2019003035 A MX2019003035 A MX 2019003035A MX 2019003035 A MX2019003035 A MX 2019003035A MX 2019003035 A MX2019003035 A MX 2019003035A
Authority
MX
Mexico
Prior art keywords
polypeptides
leprosy
vaccines
diagnosis
prevention
Prior art date
Application number
MX2019003035A
Other languages
English (en)
Inventor
G Reed Steven
S Duthie Malcolm
Original Assignee
Infectious Disease Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectious Disease Res Inst filed Critical Infectious Disease Res Inst
Publication of MX2019003035A publication Critical patent/MX2019003035A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4524—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen composiciones y métodos para prevenir, tratar y detectar la lepra. Las composiciones comprenden generalmente polipéptidos que comprenden uno o más antígenos de Mycobacterium leprae así como polinucleótidos que codifican tales polipéptidos.
MX2019003035A 2016-09-16 2017-09-15 Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra. MX2019003035A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662396074P 2016-09-16 2016-09-16
PCT/US2017/051824 WO2018053294A1 (en) 2016-09-16 2017-09-15 Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy

Publications (1)

Publication Number Publication Date
MX2019003035A true MX2019003035A (es) 2019-09-13

Family

ID=60083421

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019003035A MX2019003035A (es) 2016-09-16 2017-09-15 Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
MX2023004973A MX2023004973A (es) 2016-09-16 2019-03-15 Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023004973A MX2023004973A (es) 2016-09-16 2019-03-15 Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.

Country Status (6)

Country Link
US (2) US11801290B2 (es)
BR (1) BR112019004913B1 (es)
CA (1) CA3036218A1 (es)
MX (2) MX2019003035A (es)
PH (1) PH12019500496A1 (es)
WO (1) WO2018053294A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018053294A1 (en) 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
CN109750054B (zh) * 2019-02-21 2021-07-02 华中农业大学 一种牛支原体蛋白基因MbovGdpP及其应用
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
GB2605312B (en) 2020-03-23 2024-06-26 Hdt Bio Corp Compositions and methods for delivery of RNA
CN117120087A (zh) 2020-12-23 2023-11-24 高级健康研究所 茄尼醇疫苗助剂及其制备方法
AU2022351009A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Rna vaccines against infectious diseases
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS
WO2023049636A2 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Cancer therapy compositions and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4816566A (en) 1983-06-01 1989-03-28 Hoffmann-La Roche, Inc. Polypeptides having interferon activity
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5350681A (en) 1986-08-18 1994-09-27 The Coca-Cola Company Enzymatic membrane method for the synthesis and separation of peptides
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
WO1993023011A1 (en) 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6583266B1 (en) * 1993-08-19 2003-06-24 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to mycobacterium tuberculosis and leprae for diagnostics and therapeutics
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
DE69929444T2 (de) 1998-08-10 2006-09-28 Antigenics Inc., Woburn Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
HK1044484B (en) 1999-04-19 2005-07-29 Smithkline Beecham Biologicals S.A. Adjuvant composition containing saponin and immunostimulatory oligonucleotide
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
US7538206B2 (en) * 2001-02-22 2009-05-26 Institut Pasteur Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US7189522B2 (en) 2005-03-11 2007-03-13 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
EP2486938B1 (en) 2006-09-26 2018-05-09 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20110027348A1 (en) 2007-08-27 2011-02-03 Janos Feher Composition and method inhibiting inflammation
CN101969976A (zh) 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
EA201290072A1 (ru) * 2009-07-29 2012-12-28 Бернд Хельмут Адам Рем Полимерные частицы и их применение
MX366206B (es) * 2012-07-10 2019-07-02 Transgene Sa Vacuna de antígeno micobacteriano.
WO2018053294A1 (en) 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy

Also Published As

Publication number Publication date
BR112019004913A2 (pt) 2019-06-04
MX2023004973A (es) 2023-05-12
US20230381292A1 (en) 2023-11-30
BR112019004913B1 (pt) 2022-07-12
CA3036218A1 (en) 2018-03-22
PH12019500496A1 (en) 2019-05-27
US20200338180A1 (en) 2020-10-29
US11801290B2 (en) 2023-10-31
WO2018053294A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
MX2019003035A (es) Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
BR112018069303A2 (pt) método para tratamento de uma infecção
DK3402499T3 (da) Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes
MD3360559T2 (ro) Compoziții conținând tulpini bacteriene
MY191581A (en) Anti-pd-1 antibodies
DK3789501T3 (da) Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom
MX381160B (es) Agonistas del receptor de apelina y metodos de uso.
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
MX383376B (es) Derivado de un anillo condensado y método de preparación, compuesto intermedio, composición farmacéutica y uso del mismo.
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
HUE043259T2 (hu) Sarzskeverõ üzemeltetési eljárása, valamint sarzskeverõ az eljárás foganatosítására
MX2017000094A (es) PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS.
HUE051448T2 (hu) Imidazo[1,2a]piridinek hiperurikémia vagy köszvény kezelésére vagy megelõzésére
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MX2017005249A (es) Compuestos para usarse en el tratamiento antihelmintico.
UY36196A (es) Compuestos para usar en el tratamiento antihelmíntico
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
BR112018077458A2 (pt) proteases aspárticas
MX395175B (es) Compuesto heterocíclico aromático nitrogenado, método de preparación para el mismo, composición farmacéutica del mismo, y aplicación del mismo.
BR112017020374A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
MX388832B (es) Deteccion especifica de isoformas de clusterina.
IT201700104446A1 (it) Compositions, uses and methods for treatment of infertility and subfertility
BR112018076287A2 (pt) métodos e composições para o tratamento de doença celíaca, sensibilidade ao glúten não celíaca e doença celíaca refratária
BR112017004552A2 (pt) composições farmacêuticas